Base-edited T lymphocyte cells

PreclinicalGene therapy

NNational Institute of Allergy and Infectious Diseases (NIAID)

Base-edited T lymphocyte cells is one of 9 biologic programs targeting CD40L-HyperIgM Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CD40L-Hyperigm SyndromeRecruiting

Chronic Granulomatous Disease (CGD)Recruiting

X-Linked Severe Combined ImmunodeficiencyEnrolling by invitation

CD40L-Hyperigm SyndromePreclinical

Recruiting

Chronic Granulomatous Disease (CGD)Preclinical

Recruiting

X-Linked Severe Combined ImmunodeficiencyPreclinical

Enrolling by invitation

Competition

Competitive Landscape

9 competitors in Chronic Granulomatous Disease (CGD)

#DrugCompanyPhaseTrials

Promacta

GSK

Preclinical

1 2

Busulfex

Akero Therapeutics

Preclinical

2 3

Rapamune

PPrism Pharmaceuticals

Preclinical

2 4

Actemra

CCelltrion

Preclinical

1 5

Mozobil

GGenzyme, a Sanofi Company

Preclinical

1 6

Neupogen

EEastern Cooperative Oncology Group

Preclinical

1 7

Kepivance

SSwedish Orphan Biovitrum

Preclinical

1 8

Campath

GGenzyme, a Sanofi Company

Preclinical

1 9

Base-edited T lymphocyte cells

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

CD40L-Hyperigm Syndrome

NCT06959771

Q4 2032

PreclinicalRecruiting

Chronic Granulomatous Disease (CGD)

NCT06325709

Clinical

Trials by Indication[1]

X-linked Severe Combined Immunodeficiency1 trial

Phase 1/2 Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

Enrolling by invitation·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT06851767·18 enrolled

Chronic Granulomatous Disease (CGD)1 trial

Phase 1/2 Trial of Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-linked Chronic Granulomatous Disease

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT06325709·15 enrolled

CD40L-HyperIgM Syndrome1 trial

Base Editing Hematopoietic Stem Cell and BE T Cell Gene Therapy for CD40L-HyperIgM Syndrome-Single Patient Study

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT06959771·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Base-edited T lymphocyte cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Base-edited T lymphocyte cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Base-edited T lymphocyte cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Preclinical[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Base-edited T lymphocyte cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2032

Trials by Indication[1]

X-linked Severe Combined Immunodeficiency1 trial

Chronic Granulomatous Disease (CGD)1 trial

CD40L-HyperIgM Syndrome1 trial

References

Drug Info

Quick Facts

Related News